TY - JOUR
T1 - Comparison of management patterns and clinical outcomes in patients with atrial fibrillation in Canada and the United States (from the Analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Database)
AU - O'Hara, Gilles E.
AU - Charbonneau, Lyne
AU - Chandler, Mary
AU - Vidaillet, Humberto J.
AU - Philippon, François
AU - Sami, Magdi
AU - Rocco, Thomas A.
AU - Padder, Farooq A.
AU - Champagne, Jean
AU - Pratt, Craig M.
AU - Coutu, Benoit
AU - Wyse, D. George
N1 - Funding Information:
This study was supported by Contract N01-HC-55139 from the National Heart, Lung and Blood Institute, Bethesda, Maryland.
PY - 2005/9/15
Y1 - 2005/9/15
N2 - Little is known about differences in practice patterns or outcomes in the management of patients who have atrial fibrillation in Canada compared with those in the United States (US). We evaluated the effect that the country of enrollment may have on the management patterns and clinical outcomes in patients who participated in the AFFIRM study. Three thousand four hundred patients came from the US and 660 from Canada. In the US, patients were more likely to have a history of coronary artery disease (39% vs 35%, p = 0.03), hypertension (72% vs 67%, p = 0.01), or congestive heart failure (24% vs 18%, p = 0.0002). More US participants were <65 years of age (25% vs 19%, p = 0.003). Although at randomization the use of warfarin was comparable, during follow-up Canadians were more likely to be treated with warfarin and to be therapeutically anticoagulated. Mortality rate at 5 years was higher in US patients (24% vs 16%, p = 0.001), and the composite end point (death, disabling stroke, major bleeding, cardiac arrest, or anoxic encephalopathy) was also higher in US patients (30% vs 22%, p = 0.0005). Even after adjusting for known differences in baseline characteristics, the risk of death was lower in Canada (hazard ratio 0.70, p = 0.02). In conclusion, in the AFFIRM study, US subjects were more likely to have preexisting cardiovascular diseases despite being younger (<65 years old) than those in Canada. Effective warfarin therapy was more commonly employed in Canada. After correcting for the known differences in baseline characteristics, Canadian patients who had atrial fibrillation had a lower mortality risk.
AB - Little is known about differences in practice patterns or outcomes in the management of patients who have atrial fibrillation in Canada compared with those in the United States (US). We evaluated the effect that the country of enrollment may have on the management patterns and clinical outcomes in patients who participated in the AFFIRM study. Three thousand four hundred patients came from the US and 660 from Canada. In the US, patients were more likely to have a history of coronary artery disease (39% vs 35%, p = 0.03), hypertension (72% vs 67%, p = 0.01), or congestive heart failure (24% vs 18%, p = 0.0002). More US participants were <65 years of age (25% vs 19%, p = 0.003). Although at randomization the use of warfarin was comparable, during follow-up Canadians were more likely to be treated with warfarin and to be therapeutically anticoagulated. Mortality rate at 5 years was higher in US patients (24% vs 16%, p = 0.001), and the composite end point (death, disabling stroke, major bleeding, cardiac arrest, or anoxic encephalopathy) was also higher in US patients (30% vs 22%, p = 0.0005). Even after adjusting for known differences in baseline characteristics, the risk of death was lower in Canada (hazard ratio 0.70, p = 0.02). In conclusion, in the AFFIRM study, US subjects were more likely to have preexisting cardiovascular diseases despite being younger (<65 years old) than those in Canada. Effective warfarin therapy was more commonly employed in Canada. After correcting for the known differences in baseline characteristics, Canadian patients who had atrial fibrillation had a lower mortality risk.
UR - http://www.scopus.com/inward/record.url?scp=24944491712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944491712&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2005.05.027
DO - 10.1016/j.amjcard.2005.05.027
M3 - Article
C2 - 16169368
AN - SCOPUS:24944491712
SN - 0002-9149
VL - 96
SP - 815
EP - 821
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 6
ER -